2018 Virtual Symposium: Management of T2DM Patients with Diabetic Kidney Disease: Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Disease Progression

Kidney disease has been recognized as a complication of type 2 diabetes mellitus (T2DM) since the 1950s, developing in approximately 35% of patients with T2DM and affecting as many as 50% of patients with diabetes through a 20 years' duration. The prevalence of diabetic kidney disease (DKD) in the United States increased from 1988 to 2008 in proportion to the prevalence of diabetes. Among adults with diabetes, the prevalence of DKD has remained stable despite increased use of antihyperglycemic agents and renin-angiotensin-aldosterone system (RAAS) inhibitors.

Newer glucose-lowering agents appear to have glucose-independent effects on diabetic nephropathy and its progression. Recently published data from clinical trials assessing cardiovascular outcomes of SGLT2 inhibitors and GLP-1 receptor agonists (RAs) show positive affects on the development and progression of DKD.

This virtual symposium will utilize interactive infographics to provide an overview of the renal effects of antiglycemic agents, particularly GLP-1 RAs and SGLT2 inhibitors. Experts will identify patients who are at the greatest risk for DKD, discuss the underlying physiology of DKD, provide an overview of the mechanisms of action of SGLT2 inhibitors and GLP-1 RAs in relation to renal physiology, and how to effectively manage patients with T2DM and DKD based on the benefits and risks of SGLT2 inhibitors and GLP-1 RAs.

Identifying DKD in Patients with T2DM: Causes of and Risk Factors

Presenter: Matthew R. Weir, MD

Navigating the Guidelines for Treatment of T2DM Patients with DKD

Presenter: Robert D. Toto, MD

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Presenter: Lance Sloan, MD, FACE, FASN

Patient Case Study

Presenter: Lance Sloan, MD, FACE, FASN

Faculty: Matthew R. Weir, MDRobert D. Toto, MD

Audience Q&A

Presenter: Matthew R. Weir, MDRobert D. Toto, MDLance Sloan, MD, FACE, FASN